Assembly Bill A6927

2025-2026 Legislative Session

Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy

download bill text pdf

Sponsored By

Current Bill Status - In Assembly Committee

  • Introduced
    • In Committee Assembly
    • In Committee Senate
    • On Floor Calendar Assembly
    • On Floor Calendar Senate
    • Passed Assembly
    • Passed Senate
  • Delivered to Governor
  • Signed By Governor

Do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.
Actions

co-Sponsors

2025-A6927 (ACTIVE) - Details

See Senate Version of this Bill:
S6422
Current Committee:
Assembly Higher Education
Law Section:
Education Law
Laws Affected:
Amd §§6807 & 6810, Ed L; add §280-d, Pub Health L

2025-A6927 (ACTIVE) - Summary

Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

2025-A6927 (ACTIVE) - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   6927
 
                        2025-2026 Regular Sessions
 
                           I N  A S S E M B L Y
 
                              March 18, 2025
                                ___________
 
 Introduced by M. of A. SIMONE -- read once and referred to the Committee
   on Higher Education
 
 AN ACT to amend the education law and the public health law, in relation
   to prescription labels for mifepristone, misoprostol, gonadotropin-re-
   leasing  hormone  agonists,  pubertal suppressants, anabolic steroids,
   alpha reductase inhibitors, progestins, or drug  classes  for  hormone
   replacement therapy for treatment of gender dysphoria
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Paragraph b-1 of subdivision  1  of  section  6807  of  the
 education  law, as added by chapter 7 of the laws of 2025, is amended to
 read as follows:
   b-1. Notwithstanding paragraph b of  this  section,  the  prescription
 label  for  mifepristone,  misoprostol, [and their generic alternatives]
 GONADOTROPIN-RELEASING HORMONE AGONISTS, PUBERTAL SUPPRESSANTS, ANABOLIC
 STEROIDS, ALPHA REDUCTASE INHIBITORS, PROGESTINS, OR  DRUG  CLASSES  FOR
 HORMONE  REPLACEMENT  THERAPY  FOR  TREATMENT  OF  GENDER DYSPHORIA, may
 include the name OR ADDRESS  of  the  dispensing  health  care  practice
 instead of the name of the dispenser.
   § 2. Subdivision 1-a of section 6810 of the education law, as added by
 chapter 7 of the laws of 2025, is amended to read as follows:
   1-a.   Notwithstanding   subdivision  one  of  this  section,  at  the
 prescriber's request, the prescription label for mifepristone, misopros-
 tol, [and their  generic  alternatives]  GONADOTROPIN-RELEASING  HORMONE
 AGONISTS,  PUBERTAL  SUPPRESSANTS,  ANABOLIC  STEROIDS,  ALPHA REDUCTASE
 INHIBITORS, PROGESTINS, OR DRUG CLASSES FOR HORMONE REPLACEMENT  THERAPY
 FOR TREATMENT OF GENDER DYSPHORIA, may include the name of the prescrib-
 ing health care practice instead of the name of the prescriber.
   § 3. The public health law is amended by adding a new section 280-d to
 read as follows:
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD10852-01-5
 A. 6927                             2

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.